30% of Diabetes Patients Admit Skipping Insulin Injections
Add bookmark
30% of Diabetes Patients Admit Skipping Insulin Injections
Add bookmark
Patricia DeCock, Medical Affairs Manager Diabetes at Sanofi Aventis, joins Pharma IQ to discuss the problems associated with patient adherence to treatment of Type 1 and 2 diabetes, in paediatrics, adolescents and adults. In this exclusive interview, DeCock outlines the origins and remedies of each diabetes type, the development of hypoglycaemia, psychological impact on diabetes sufferers and the ramifications for treatment compliance.
[inlinead]
Tags:
Patricia DeCock
Sanofi Aventis
patient adherence
Type 1 and 2 diabetes
medical affairs
patient compliance
global patient compliance
global patient adherence
Insulin injections
diabetes
